ライフサイエンスコーパス: allergic rhinitis

1 with known risk factors for asthma, such as allergic rhinitis).

2 sensitization was found mainly in those with allergic rhinitis.

3 on is sensitized giving a high prevalence of allergic rhinitis.

4 henotype was only positively associated with allergic rhinitis.

5 lls from children and adults with asthma and allergic rhinitis.

6 ntradermal immunotherapy in the treatment of allergic rhinitis.

7 e and reflects the real-life epidemiology of allergic rhinitis.

8 or combination pharmacotherapy for seasonal allergic rhinitis.

9 an effective, safe treatment for HDM-induced allergic rhinitis.

10 ch, which includes food allergy, asthma, and allergic rhinitis.

11 k of asthma, aeroallergen sensitization, and allergic rhinitis.

12 eous immunotherapy are effective in seasonal allergic rhinitis.

13 nd an apparent reduction in the incidence of allergic rhinitis.

14 m 25(OH)D levels at any time point with ever allergic rhinitis.

15 and subsequent wheeze/asthma, eczema and/or allergic rhinitis.

16 outcome assessment in patients with seasonal allergic rhinitis.

17 ncy may have beneficial effects on childhood allergic rhinitis.

18 were efficacious in treating HDM-associated allergic rhinitis.

19 .53; 1.24-1.89), but was not associated with allergic rhinitis.

20 oxazosin might produce beneficial effects in allergic rhinitis.

21 ns in nasal secretion (r = 0.69, P = .06) in allergic rhinitis.

22 d adults with moderate to severe HDM-induced allergic rhinitis.

23 ines are characteristic features of seasonal allergic rhinitis.

24 airway epithelial cells in type 2 asthma and allergic rhinitis.

25 pe 1 allergic disorders including asthma and allergic rhinitis.

26 ause of overlap with other diseases, such as allergic rhinitis.

27 have a reported diagnosis of food allergy or allergic rhinitis.

28 lergy, atopic dermatitis/eczema, asthma, and allergic rhinitis?

29 ng patients with moderate to severe seasonal allergic rhinitis, 2 years of sublingual grass pollen im

30 ratio [OR] 1.89, 95% CI 1.26-2.84; p=0.004), allergic rhinitis (3.06, 2.26-4.15; p<0.0001), childhood

31 Most common comorbidities were allergic rhinitis (62.4%), gastroesophageal reflux (42.1

32 In allergic rhinitis, a relevant outcome providing informat

33 obesity was associated with reduced odds of allergic rhinitis (adjusted odds ratio, 0.35; 95% CI, 0.

34 0 [95% CI, -1.55 to -0.06]; P = 0.0348), and allergic rhinitis (adjusted odds ratio, 4.83 [95% CI, 1.

35 for specific areas of allergology, including allergic rhinitis, aerobiology, allergen immunotherapy,

36 Allergic rhinitis affects approximately one in four of t

37 No subject had a history of asthma/allergic rhinitis: all had negative results for aeroalle

38 topic diseases, including food allergy (FA), allergic rhinitis, allergic asthma, and allergic rhinoco

39 en immunotherapy (AIT) for the management of allergic rhinitis, allergic asthma, IgE-mediated food al

40 o allergic conditions (food allergy, asthma, allergic rhinitis, allergic conjunctivitis, and eosinoph

41 Non-allergic rhinitis also is a risk factor for the developm

42 d associations of residential greenness with allergic rhinitis and aeroallergen sensitization based o

43 ness appears to be associated with childhood allergic rhinitis and aeroallergen sensitization, the ef

44 The number of genes related to allergic rhinitis and allergic asthma increases steadily

45 m the house dust mite and is associated with allergic rhinitis and allergic asthma.

46 ly disease-modifying treatment available for allergic rhinitis and allergic asthma.

47 ations for the exploration of biomarkers for allergic rhinitis and allergic asthma.

48 and ascertain its association with childhood allergic rhinitis and allergic sensitization.

49 reatment was well tolerated in patients with allergic rhinitis and appears to reduce allergic respons

50 d contribute to the onset and aggravation of allergic rhinitis and asthma among other chronic respira

51 Allergic rhinitis and asthma constitute two clinical exp

52 Allergen immunotherapy (AIT) treatment for allergic rhinitis and asthma is used by 2.6 million Amer

53 i.e. the Allergy Diary and CARAT: Control of Allergic Rhinitis and Asthma Test) in 22 Reference Sites

54 ed allergic diseases, including respiratory (allergic rhinitis and asthma) and skin (atopic dermatiti

55 It is widely believed that for allergic rhinitis and asthma, avoidance of specific trig

56 ses to reflect the real-life epidemiology of allergic rhinitis and asthma.

57 is effective in patients with IgE-dependent allergic rhinitis and asthma.

58 blets has been demonstrated in patients with allergic rhinitis and asthma.

59 ) the duration of any human milk feeding and allergic rhinitis and atopic dermatitis in childhood.

60 rst App (iOS and Android) to have tested for allergic rhinitis and conjunctivitis.

61 UFAs were associated with increased risks of allergic rhinitis and eczema up to 18 years, and sensiti

62 has variable preventative effects on asthma, allergic rhinitis and eczema up to adolescence.

63 The results for allergic rhinitis and eczema were less consistent.

64 role in refractory disorders such as asthma, allergic rhinitis and food allergy, mainly by inducing T

65 outcomes (asthma, wheeze, atopic dermatitis, allergic rhinitis and IgE) were assessed across the stud

66 The Allergic Rhinitis and its Impact on Asthma (ARIA) initia

67 llergy and Asthma European Network (Ga2len), Allergic Rhinitis and Its Impact on Asthma (ARIA), and t

68 technologies in rhinitis control, the ARIA (Allergic Rhinitis and its Impact on Asthma) score rangin

69 Allergic rhinitis and LAR share many clinical features i

70 , while the effect is mainly confined to non-allergic rhinitis and more pronounced in adolescents tha

71 tion pilot study, 18 subjects with perennial allergic rhinitis and sensitization to HDM were exposed

72 trospective study, we enrolled patients with allergic rhinitis and sensitization to house dust mites.

73 eczema, childhood wheeze/asthma, eczema and allergic rhinitis and young adult asthma.

74 n and Central Europe and is a major cause of allergic rhinitis and, possibly, asthma symptoms.

75 treatment of house dust mites (HDM)-induced allergic rhinitis and/or asthma based on recent real-lif

76 with HDM mite allergoid in the treatment of allergic rhinitis and/or asthma.

77 d with allergic disease (asthma, eczema, and allergic rhinitis) and corticosteroid use.

78 Asthma, hay fever (or allergic rhinitis) and eczema (or atopic dermatitis) oft

79 Outcomes were offspring's current asthma, allergic rhinitis, and allergen sensitization at a media

80 Atopic dermatitis (AD), food allergy, allergic rhinitis, and asthma are common atopic disorder

81 004), but no effect on atopic sensitization, allergic rhinitis, and asthma at 6 years.

82 led that Down syndrome, astigmatism, myopia, allergic rhinitis, and asthma were positively associated

83 ergic diseases, including atopic dermatitis, allergic rhinitis, and asthma.

84 Evidence on food allergies, allergic rhinitis, and atopic dermatitis is limited.

85 nically as atopic diseases including asthma, allergic rhinitis, and atopic dermatitis.

86 Allergic disorders include food allergy, allergic rhinitis, and certain forms of asthma resulting

87 predicted values, whereas chronic sinusitis, allergic rhinitis, and gastroesophageal reflux disease w

88 morbidities, including food allergy, asthma, allergic rhinitis, and mental health disorders.

89 hyperreactivity (BHR), flexural eczema (FE), allergic rhinitis, and sensitization in childhood and ea

90 sis (asthma aOR = 2.61 [95% CI = 2.14-3.18]; allergic rhinitis aOR = 1.96 [95% CI = 1.58-2.42]; eosin

91 K-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) App (Allergy Diary) assesses allergic

92 K-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) app (Allergy Diary) on smartphones sc

93 Allergic rhinitis (AR) and asthma are common allergic co

94 epithelial barrier is found in patients with allergic rhinitis (AR) and asthma; however, the underlyi

95 thin existing adult treatment algorithms for allergic rhinitis (AR) and chronic rhinosinusitis (CRS).

96 parent-reported physician-diagnosed asthma, allergic rhinitis (AR) and eczema, as well as spirometri

97 Allergic rhinitis (AR) and local allergic rhinitis (LAR)

98 (NAC) is a useful tool for the diagnosis of allergic rhinitis (AR) and local allergic rhinitis (LAR)

99 This comprehensive practice parameter for allergic rhinitis (AR) and nonallergic rhinitis (NAR) pr

100 Baseline allergic rhinitis (AR) and peanut SPT wheal size were si

101 immunotherapy is effective in patients with allergic rhinitis (AR) and, unlike antiallergic drugs, h

102 mmunotherapy (AIT) is the only treatment for allergic rhinitis (AR) and/or allergic asthma (AA) with

103 Asthma and allergic rhinitis (AR) are common allergic comorbidities

104 l allergy symptoms (OAS) (4.46 [4.19-4.75]), allergic rhinitis (AR) comorbidity (2.82 [2.68-2.95]), a

105 nsights into optimizing treatment to improve allergic rhinitis (AR) control.

106 lection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several factors, inclu

107 mmunotherapy (AIT) in seasonal and perennial allergic rhinitis (AR) depends on the definition of poll

108 on of all 10 TLR genes for associations with allergic rhinitis (AR) detected a number of significant

109 lted in a decreased probability of having an allergic rhinitis (AR) exacerbation day (from 11% [place

110 Allergic rhinitis (AR) is caused by immunoglobulin E (Ig

111 Allergic rhinitis (AR) is characterized by mucosal infla

112 f asthma whereas evidence for remodelling in allergic rhinitis (AR) is conflicting.

113 es research on medical care and treatment of allergic rhinitis (AR) is scarce.

114 Moderate-to-severe allergic rhinitis (AR) may increase the risk of developi

115 sidered the first step in the development of allergic rhinitis (AR) or an independent phenotype.

116 ents who received at least three symptomatic allergic rhinitis (AR) prescriptions in successive mite

117 Diagnoses of current allergic rhinitis (AR) related to mite allergy and asthm

118 allergen challenge (NAC) is a human model of allergic rhinitis (AR) that delivers standardized allerg

119 unotherapy (AIT) prevents the progression of allergic rhinitis (AR) to asthma.

120 sociation between periodontitis and previous allergic rhinitis (AR) using a matched patient-control s

121 Allergic rhinitis (AR) was defined as one or more positi

122 the only disease-modifying intervention for allergic rhinitis (AR) with long-term efficacy.

123 Allergic rhinitis (AR), allergic conjunctivitis (AC), an

124 Guidelines on the treatment of asthma, allergic rhinitis (AR), and allergen immunotherapy (AIT)

125 lergen provocation test (NAPT) into the LAR, allergic rhinitis (AR), and nonallergic rhinitis (NAR) p

126 ssessment of current atopic dermatitis (AD), allergic rhinitis (AR), asthma and sensitization against

127 Allergic rhinitis (AR), chronic rhinosinusitis (CRS) and

128 icant impairment of quality of life (QoL) in allergic rhinitis (AR), the degree of impairment in QoL

129 Despite the socioeconomic importance of allergic rhinitis (AR), very few prospective studies hav

130 es and subsequent risk for diseases, such as allergic rhinitis (AR).

131 new therapeutic targets and/or biomarkers of allergic rhinitis (AR).

132 (both 1 spray/nostril bid), in children with allergic rhinitis (AR).

133 allergic inflammation seen in patients with allergic rhinitis (AR).

134 n adults with moderate-to-severe HDM-induced allergic rhinitis (AR).

135 kers to diagnose and characterize asthma and allergic rhinitis (AR).

136 ithelial TJs remain unknown in patients with allergic rhinitis (AR).

137 -mediated food allergy [IgE-FA], asthma, and allergic rhinitis [AR]) was ascertained in a pediatric p

138 pinnings associated with the pathogenesis of allergic rhinitis are not entirely clear.

139 tions related to the treatment of asthma and allergic rhinitis as primary outcomes.

140 Rates of allergic rhinitis, asthma and other food allergies in Pw

141 n atopic dermatitis (AD), food allergy (FA), allergic rhinitis, asthma, and atopic sensitization at 6

142 roallergen sensitization, atopic dermatitis, allergic rhinitis, asthma, and challenge-proved food all

143 implicated in the pathophysiology of eczema, allergic rhinitis, asthma, and food allergy.

144 be clinically effective and safe in treating allergic rhinitis, asthma, and stinging insect allergy i

145 ified from four recent systematic reviews on allergic rhinitis, asthma, food allergy and venom allerg

146 The prevalence of allergic diseases such as allergic rhinitis, asthma, food allergy, and atopic derm

147 likely to have KC, and patients with asthma, allergic rhinitis, astigmatism, myopia, or Down syndrome

148 eases, with strong associations observed for allergic rhinitis at 12 (OR = 5.69[95% CI: 1.83,17.60] p

149 adjusted OR 3.45, 95% CI 1.07-11.74), as was allergic rhinitis at 5-7 years of age (adjusted OR 4.06,

150 500-m buffer was positively associated with allergic rhinitis at 6-8 years in BAMSE (odds ratio = 1.

151 valence of food allergy, asthma, eczema, and allergic rhinitis at age 4 years.

152 were collected from 40 adults with seasonal allergic rhinitis at baseline and at 4, 8, 16, 28, and 5

153 ciated with 21% and 20% reduced odds of ever allergic rhinitis at school age (odds ratios of 0.79 [95

154 by bottle versus breast with food allergies, allergic rhinitis, atopic dermatitis, and asthma.

155 Allergic rhinitis, atopic eczema and food hypersensitivi

156 For allergic rhinitis, authors focused on the prediction of

157 associated with inflammatory responses as in allergic rhinitis but can also occur in the absence of i

158 of follow-up revealed significant effects in allergic rhinitis by measuring the number of AR medicati

159 cuss how the development of some symptoms in allergic rhinitis can serve as clues for new-onset COVID

160 e to develop chronic inflammation as seen in allergic rhinitis, chronic rhinosinusitis, and asthma.

161 es in relation to diagnosis and treatment of allergic rhinitis, chronic rhinosinusitis, and asthma.

162 age, gender, presence of symptoms of asthma, allergic rhinitis, chronic rhinosinusitis, smoking statu

163 nal linkage of the 4q35 region to asthma and allergic rhinitis comorbidity (AAR; P = 7.2 x 10(-5)).

164 , wheezing/asthma; six, food allergy; three, allergic rhinitis/conjunctivitis.

165 Mobile technology has been used to appraise allergic rhinitis control, but more data are needed.

166 However, a large majority of subjects with allergic rhinitis do not develop asthma, suggesting dive

167 Allergic rhinitis (doctor diagnosis/symptoms) and aeroal

168 Asthma, allergic rhinitis, eosinophil count of at least 150 cell

169 Clinical factors, including asthma, allergic rhinitis, eosinophil count of at least 150 cell

170 racterized by a higher prevalence of asthma, allergic rhinitis, eosinophil count of at least 150 cell

171 diagnosis and management of allergic and non-allergic rhinitis, first published in 2007.

172 Main Outcomes and Measures: Wheeze, eczema, allergic rhinitis, food allergy, allergic sensitization,

173 3 years, children were assessed for asthma, allergic rhinitis, food allergy, and atopic dermatitis.

174 ns resulting in conditions including asthma, allergic rhinitis, food allergy, and atopic dermatitis.

175 diseases such as atopic dermatitis, asthma, allergic rhinitis, food allergy, contact allergy, and ha

176 We propose the term dual allergic rhinitis for this rhinitis phenotype.

177 ) of current asthma, allergen sensitization, allergic rhinitis, fractional exhaled nitric oxide (FeNO

178 al immunotherapy tablets in the treatment of allergic rhinitis has been firmly established in large m

179 Sublingual immunotherapy for allergic rhinitis has been used successfully for years i

180 Research efforts in allergic rhinitis have always been intense.

181 ic sensitization in adolescence will develop allergic rhinitis in adult life.

182 sitization in adolescence, 53%-78% developed allergic rhinitis in adulthood.

183 or central obesity were not associated with allergic rhinitis in adults.

184 SCIT was effective for allergic rhinitis in childhood.

185 considered as a choice for the treatment of allergic rhinitis in childhood.

186 and subsequent climate change on asthma and allergic rhinitis in children and adults and addresses t

187 opic dermatitis during infancy to asthma and allergic rhinitis in later childhood.

188 tom loads for grass and birch pollen-induced allergic rhinitis in other European geographical areas s

189 We investigated SCIT for allergic rhinitis in our hospital for the past 17 years.

190 initial pharmacologic treatment of seasonal allergic rhinitis in patients aged 12 years or older.

191 ndation 1: For initial treatment of seasonal allergic rhinitis in persons aged 12 years or older, rou

192 For treatment of moderate to severe seasonal allergic rhinitis in persons aged 12 years or older, the

193 ndation 2: For initial treatment of seasonal allergic rhinitis in persons aged 15 years or older, rec

194 The occurrence of so-called local allergic rhinitis in the absence of systemic IgE will be

195 rapy provides a new option for patients with allergic rhinitis in the United States.

196 xamined whether having pollinosis (a form of allergic rhinitis) in a follow-up survey could predict a

197 The prevalence of allergic sensitisation and allergic rhinitis increased in a general adult Danish po

198 cence (31%) to adulthood (57%); particularly allergic rhinitis increased with an incidence rate of 17

199 Allergic rhinitis induced by house dust mites (HDMs) is

200 hitis, sinusitis, pharyngitis, otitis media, allergic rhinitis, influenza, pneumonia, and unspecified

201 In allergic rhinitis, initial allergen exposure and sensiti

202 lt patients with moderate to severe seasonal allergic rhinitis (interfering with usual daily activiti

203 Allergic rhinitis is common and affects 10-15% of childr

204 Allergic rhinitis is diagnosed by history and examinatio

205 The prevalence of allergic rhinitis is high, but the role of environmental

206 notherapy as compared to pharmacotherapy for allergic rhinitis is the long-term effect that persists

207 hinitis (Mobile Airways Sentinel NetworK for allergic rhinitis) is a patient-centred ICT system.

208 rmatitis, food allergy, allergic asthma, and allergic rhinitis, it is logical that restoring the skin

209 linical trial for Japanese children with HDM allergic rhinitis (JapicCTI-152953).

210 iagnosis of allergic rhinitis (AR) and local allergic rhinitis (LAR) and might serve to design and mo

211 Allergic rhinitis (AR) and local allergic rhinitis (LAR) are defined by nasal reactivity

212 cts of allergen immunotherapy (AIT) on local allergic rhinitis (LAR) are largely unknown.

213 knowledge about the natural history of local allergic rhinitis (LAR) is limited.

214 nd have defined a new phenotype called local allergic rhinitis (LAR) or 'entopy'.

215 Over 30% of local allergic rhinitis (LAR) patients self-report bronchial s

216 shown to be an effective treatment for local allergic rhinitis (LAR) to house dust mites.

217 lergic rhinitis (SAR), eight perennial local allergic rhinitis (LAR), six nonallergic rhinitis (NAR),

218 This disease phenotype has been termed local allergic rhinitis (LAR).

219 Baker's rhinitis is a kind of occupational allergic rhinitis mainly caused by intranasal exposure t

220 Non-allergic rhinitis may be a presenting complaint for syst

221 , when used in patients with both asthma and allergic rhinitis, may be cost-effective with an increme

222 The probability of having had allergic rhinitis medication prescribed was also reduced

223 There was no association between KCN and allergic rhinitis, mitral valve disorder, aortic aneurys

224 KC included diabetes mellitus (DM), asthma, allergic rhinitis, mitral valve prolapse, collagen vascu

225 cipants without allergy (n = 12), those with allergic rhinitis (n = 12), or those with allergic rhini

226 , exceeding that in a comparator cohort with allergic rhinitis (n = 149).

227 on with patients suffering from IgE-mediated allergic rhinitis (n=10) and healthy controls (n=10).

228 Participants with allergic rhinitis (n=42) were randomized to receive eigh

229 Female gender, allergic rhinitis, obesity, and family history of asthma

230 nvestigated the cost-effectiveness of AIT in allergic rhinitis, of which seven were based on data fro

231 Allergic rhinitis often impairs social life and performa

232 y promote these biomarkers to become part of allergic rhinitis or allergic asthma classifiers with hi

233 Participants with allergic rhinitis or allergic rhinitis with asthma had i

234 t been increased in patients with asthma and allergic rhinitis or in acutely exuding healthy airways.

235 tal asthma (OR, 1.56; 95% CI, 1.18-2.05) and allergic rhinitis (OR, 1.68; 95% CI, 1.34-2.11) had a sm

236 , 3.07-10.52] and 4.56 [95% CI, 2.35-8.52]), allergic rhinitis (OR, 22.4 [95% CI, 11.67-44.54] and 13

237 degree relative with parent-reported eczema, allergic rhinitis, or asthma, diagnosed by a doctor).

238 cognizes the increased occurrence of asthma, allergic rhinitis, or both after atopic dermatitis (AD)

239 served atopic march from early AD to asthma, allergic rhinitis, or both later in life and the extensi

240 Perennial allergic rhinitis (PAR) represents a global and public h

241 asonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).

242 In PBMCs of allergic rhinitis participants, 42 sites showed signific

243 ach group of donors (32 healthy controls, 43 allergic rhinitis patients and 192 asthmatics with diffe

244 AS) is a validated tool to assess control in allergic rhinitis patients.

245 ve" of respiratory allergy, i.e., asthma and allergic rhinitis, plaguing westernized countries, with

246 , eczema (pooled OR 2.7; 95% CI 1.7-4.4) and allergic rhinitis (pooled OR 3.1; 95% CI 1.9-4.9) from 4

247 Allergic rhinitis prevalence was similar in all groups (

248 Forty-one patients with allergic rhinitis received idelalisib/placebo (n = 21) o

249 design trial, 37 participants with seasonal allergic rhinitis received suboptimal SCIT (30,000 stand

250 l obesity is associated with reduced odds of allergic rhinitis, regardless of sex.

251 participants with severe persistent seasonal allergic rhinitis resulted in tissue eosinophilia and in

252 T)-tablets with pharmacotherapy for seasonal allergic rhinitis (SAR) and perennial allergic rhinitis

253 s in a panel study of subjects with seasonal allergic rhinitis (SAR) and subjects without allergy and

254 Seasonal allergic rhinitis (SAR) caused by intermittent exposure

255 In previous research, patients with seasonal allergic rhinitis (SAR) showed poorer school and work pe

256 rom the discrepant group and in six seasonal allergic rhinitis (SAR), eight perennial local allergic

257 patients with grass pollen allergy (seasonal allergic rhinitis [SAR] group, n = 16), sublingual immun

258 3 untreated allergic patients (with seasonal allergic rhinitis [SAR]), and 12 nonatopic control subje

259 iations between vitamin D exposure with ever allergic rhinitis, serum total IgE level, and allergen s

260 shows that families with eczema, asthma, or allergic rhinitis should not use daily emollients to try

261 Changes in sIgE-defined and SPT-defined allergic rhinitis showed similar increasing trends.

262 e efficacy was assessed by reductions in the allergic rhinitis symptom-medication score, and the asth

263 e HDM group displayed a 57% reduction in the allergic rhinitis symptom-medication score, which was ma

264 gy Diary) on smartphones screens to evaluate allergic rhinitis symptoms and disease control.

265 asal responses in some patients with typical allergic rhinitis symptoms but without atopy and have de

266 acy of continuous vs on-demand treatment for allergic rhinitis symptoms is still a matter of debate.

267 Allergic rhinitis symptoms may commence as early as the

268 ergic rhinitis) App (Allergy Diary) assesses allergic rhinitis symptoms, disease control and impact o

269 est novel concepts and research questions in allergic rhinitis that may not be identified using class

270 Here we show in humans suffering from allergic rhinitis that merely reencountering the environ

271 The risk factors for asthma (e.g., allergic rhinitis) that were identified either by NLP or

272 dds ratio [OR], 0.69 [95% CI, 0.53-0.89] for allergic rhinitis), the sum of the n-3 PUFAs eicosapenta

273 In patients with allergic rhinitis, the broader the IgE molecular sensiti

274 Male gender, allergic rhinitis, the presence of dysphagia, and younge

275 Allergic rhinitis to grass pollen (ARg) was defined as u

276 assigned 93 adults with grass pollen-induced allergic rhinitis to receive 7 preseasonal intradermal a

277 The Gauging Response in Allergic Rhinitis to Sublingual and Subcutaneous Immunot

278 he clinical development programs of selected allergic rhinitis treatments were evaluated.

279 ng nasal allergen challenge in subjects with allergic rhinitis using novel noninvasive methodology.

280 Allergic rhinitis was defined as physician-diagnosed hay

281 Allergic rhinitis was defined as sensitisation and self-

282 Allergic rhinitis was reported by 167 (20%) subjects.

283 Childhood predictors for adult allergic rhinitis were atopic dermatitis, asthma and asy

284 Data on asthma, eczema, and allergic rhinitis were captured by validated Internation

285 Symptoms of allergic rhinitis were controlled (VAS-global <20) in ap

286 Asthma and allergic rhinitis were diagnosed based on predefined alg

287 uble-blind study, adults with HDM-associated allergic rhinitis were given a daily sublingual tablet c

288 Risks of allergic rhinitis were not associated with birth weight.

289 Important risk factors for allergic rhinitis were parental rhinitis (adjusted OR =

290 ether or not remodelling may be a feature of allergic rhinitis will be reviewed.

291 th allergic rhinitis (n = 12), or those with allergic rhinitis with asthma (n = 11).

292 Participants with allergic rhinitis or allergic rhinitis with asthma had increased IFN-alpha2a,

293 at AIT may be cost-effective for people with allergic rhinitis with or without asthma and in high-ris

294 ty-two adult patients (19-61 years old) with allergic rhinitis with or without asthma caused by grass

295 e to allergen immunotherapy in patients with allergic rhinitis with or without asthma.

296 in North American subjects with HDM-induced allergic rhinitis with or without conjunctivitis (AR/C).

297 Perennial allergic rhinitis with seasonal exacerbations is the mos

298 Perennial allergic rhinitis with seasonal exacerbations was most c

299 epithelial permeability has been reported in allergic rhinitis, with histamine and type-2 inflammatio

300 CysLT1R) are widely used to treat asthma and allergic rhinitis, with variable response rates.